产品名称：Human PD-L1 Antibody (Durvalumab, Research Use)
产品编号：NBR-0073
针对靶点：PD-L1
抗体药商品名：Durvalumab
抗体药描述：Durvalumab (trade name Imfinzi) is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca.[6] It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279). 产品外观：Transparent Liquid
分子量：~150kDa
CAS：N/A
溶解度：Water; PBS, TBS Buffer等
表达系统：CHO Expressed
抗体亚型：Ab. Isotype - IgG

  Gene Name: PD-L1
Synonyms: CD274; B7H1; PDL1
Target Description: Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response.
Ensembl: ENSG00000120217
Uniprot: Q9NZQ7